Biohit Oyj (BIOBV.HE)
EUR 2.55
(-0.97%)
EUR 2.55
(-0.97%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 400 Thousand EUR | -41.69% |
| 2022 | 686 Thousand EUR | 342.58% |
| 2021 | 155 Thousand EUR | 24.0% |
| 2020 | 125 Thousand EUR | 111.86% |
| 2019 | 59 Thousand EUR | 40.48% |
| 2018 | 42 Thousand EUR | -28.81% |
| 2017 | 59 Thousand EUR | 0.0% |
| 2016 | - EUR | 0.0% |
| 2015 | - EUR | 0.0% |
| 2014 | - EUR | 0.0% |
| 2013 | - EUR | 0.0% |
| 2012 | - EUR | 0.0% |
| 2011 | - EUR | -100.0% |
| 2010 | 8.54 Million EUR | 121.72% |
| 2009 | 3.85 Million EUR | -51.78% |
| 2008 | 7.99 Million EUR | -3.24% |
| 2007 | 8.26 Million EUR | 30.76% |
| 2006 | 6.31 Million EUR | -12.99% |
| 2005 | 7.26 Million EUR | 127.09% |
| 2004 | 3.19 Million EUR | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q2 | 400 Thousand EUR | 0.0% |
| 2024 Q1 | 400 Thousand EUR | 0.0% |
| 2023 Q3 | 427 Thousand EUR | -14.6% |
| 2023 FY | 400 Thousand EUR | -41.69% |
| 2023 Q2 | 500 Thousand EUR | 0.0% |
| 2023 Q4 | 400 Thousand EUR | -6.32% |
| 2023 Q1 | 500 Thousand EUR | -27.11% |
| 2022 Q4 | 686 Thousand EUR | 0.0% |
| 2022 FY | 686 Thousand EUR | 342.58% |
| 2022 Q3 | 686 Thousand EUR | -14.25% |
| 2022 Q2 | 800 Thousand EUR | 0.0% |
| 2022 Q1 | 800 Thousand EUR | 416.13% |
| 2021 Q3 | 162 Thousand EUR | -19.0% |
| 2021 Q2 | 200 Thousand EUR | 0.0% |
| 2021 Q1 | 200 Thousand EUR | 60.0% |
| 2021 FY | 155 Thousand EUR | 24.0% |
| 2021 Q4 | 155 Thousand EUR | -4.32% |
| 2020 Q1 | 100 Thousand EUR | 69.49% |
| 2020 Q2 | 100 Thousand EUR | 0.0% |
| 2020 Q3 | 131 Thousand EUR | 31.0% |
| 2020 Q4 | 125 Thousand EUR | -4.58% |
| 2020 FY | 125 Thousand EUR | 111.86% |
| 2019 Q2 | 100 Thousand EUR | 0.0% |
| 2019 FY | 59 Thousand EUR | 40.48% |
| 2019 Q1 | 100 Thousand EUR | 138.1% |
| 2019 Q4 | 59 Thousand EUR | 0.0% |
| 2019 Q3 | 59 Thousand EUR | -41.0% |
| 2018 Q2 | 100 Thousand EUR | 0.0% |
| 2018 Q3 | 42 Thousand EUR | -58.0% |
| 2018 FY | 42 Thousand EUR | -28.81% |
| 2018 Q1 | 100 Thousand EUR | 69.49% |
| 2018 Q4 | 42 Thousand EUR | 0.0% |
| 2017 Q3 | 59 Thousand EUR | -41.0% |
| 2017 FY | 59 Thousand EUR | 0.0% |
| 2017 Q2 | 100 Thousand EUR | 0.0% |
| 2017 Q4 | 59 Thousand EUR | 0.0% |
| 2017 Q1 | 100 Thousand EUR | 0.0% |
| 2016 Q4 | - EUR | 0.0% |
| 2016 Q1 | - EUR | 0.0% |
| 2016 Q2 | - EUR | 0.0% |
| 2016 Q3 | - EUR | 0.0% |
| 2016 FY | - EUR | 0.0% |
| 2015 Q2 | - EUR | 0.0% |
| 2015 Q1 | - EUR | 0.0% |
| 2015 FY | - EUR | 0.0% |
| 2015 Q4 | - EUR | 0.0% |
| 2015 Q3 | - EUR | 0.0% |
| 2014 Q3 | - EUR | 0.0% |
| 2014 FY | - EUR | 0.0% |
| 2014 Q4 | - EUR | 0.0% |
| 2014 Q2 | - EUR | 0.0% |
| 2014 Q1 | - EUR | 0.0% |
| 2013 Q1 | - EUR | 0.0% |
| 2013 Q3 | - EUR | 0.0% |
| 2013 Q4 | - EUR | 0.0% |
| 2013 Q2 | - EUR | 0.0% |
| 2013 FY | - EUR | 0.0% |
| 2012 Q4 | - EUR | 0.0% |
| 2012 Q2 | - EUR | 0.0% |
| 2012 FY | - EUR | 0.0% |
| 2012 Q3 | - EUR | 0.0% |
| 2012 Q1 | - EUR | 0.0% |
| 2011 Q1 | 8.1 Million EUR | -5.21% |
| 2011 Q3 | 9.8 Million EUR | -3.92% |
| 2011 Q2 | 10.2 Million EUR | 25.93% |
| 2011 Q4 | - EUR | -100.0% |
| 2011 FY | - EUR | -100.0% |
| 2010 Q1 | 4.8 Million EUR | 24.55% |
| 2010 Q2 | 4.7 Million EUR | -2.08% |
| 2010 FY | 8.54 Million EUR | 121.72% |
| 2010 Q3 | 4.5 Million EUR | -4.26% |
| 2010 Q4 | 8.54 Million EUR | 89.89% |
| 2009 Q4 | 3.85 Million EUR | 0.0% |
| 2009 FY | 3.85 Million EUR | -51.78% |
| 2008 FY | 7.99 Million EUR | -3.24% |
| 2007 FY | 8.26 Million EUR | 30.76% |
| 2006 FY | 6.31 Million EUR | -12.99% |
| 2005 FY | 7.26 Million EUR | 127.09% |
| 2004 FY | 3.19 Million EUR | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| Herantis Pharma Oyj | 29.84 Thousand EUR | -1240.213% |
| Nanoform Finland Oyj | 5.2 Million EUR | 92.313% |